J. Park (Uijeongbu, KR)
Eulji Medical CenterPresenter Of 1 Presentation
P086 - Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation for Repair of Articular Cartilage Defects
Abstract
Purpose
To study the efficacy and safety results at 5 years after treatment with costal chondrocyte-derived pellet-type autologous chondrocyte implantation for repair of articular cartilage defects of the knee.
Methods and Materials
This article describes the 5-year follow-up of the previous prospective clinical trial that compared the results of Costal chondrocyte-derived pellet-type autologous chondrocyte implantation versus microfracture at 2-year follow-up. Of the 20 patients from the Costal chondrocyte-derived pellet-type autologous chondrocyte implantation group that were described in the previous study, 12 were followed-up at 5 years. Clinical outcomes scores including IKDC, Lysholm, KOOS score, and 100 mm pain VAS score and MOCART score from magnetic resonance imaging was performed at 5-year follow-up.
Results
There were no treatment-related serious adverse events during the 5-year follow-up period. Significant improvements were seen in all clinical scores from the preoperative baseline to the 5-year follow-up (IKDC score, from 38.2 to 70.7, P < 0.0006; Lysholm score, from 47.5 to 81.7, P < 0.0003; and KOOS score, from 54.1 to 82.5, P < 0.0022; 100 mm pain VAS score, from 59.3 to 17.2, P < 0.0001). Significant improvement was seen in MOCART score from preoperative baseline to the 5-year follow-up (18.1 to 70.9, P < 0.0001).
Conclusion
The overall results of the 5-year follow-up of this clinical trial suggest that the efficacy and safety of CCP-ACI were well maintained at 5-year follow-up.
Presenter Of 1 Presentation
P086 - Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation for Repair of Articular Cartilage Defects
Abstract
Purpose
To study the efficacy and safety results at 5 years after treatment with costal chondrocyte-derived pellet-type autologous chondrocyte implantation for repair of articular cartilage defects of the knee.
Methods and Materials
This article describes the 5-year follow-up of the previous prospective clinical trial that compared the results of Costal chondrocyte-derived pellet-type autologous chondrocyte implantation versus microfracture at 2-year follow-up. Of the 20 patients from the Costal chondrocyte-derived pellet-type autologous chondrocyte implantation group that were described in the previous study, 12 were followed-up at 5 years. Clinical outcomes scores including IKDC, Lysholm, KOOS score, and 100 mm pain VAS score and MOCART score from magnetic resonance imaging was performed at 5-year follow-up.
Results
There were no treatment-related serious adverse events during the 5-year follow-up period. Significant improvements were seen in all clinical scores from the preoperative baseline to the 5-year follow-up (IKDC score, from 38.2 to 70.7, P < 0.0006; Lysholm score, from 47.5 to 81.7, P < 0.0003; and KOOS score, from 54.1 to 82.5, P < 0.0022; 100 mm pain VAS score, from 59.3 to 17.2, P < 0.0001). Significant improvement was seen in MOCART score from preoperative baseline to the 5-year follow-up (18.1 to 70.9, P < 0.0001).
Conclusion
The overall results of the 5-year follow-up of this clinical trial suggest that the efficacy and safety of CCP-ACI were well maintained at 5-year follow-up.